In an APP/APOE knockout mouse, inhibition of the TGFB/SMAD2 pathway activity in astrocytes has been shown to increase amyloid plaque formation and cognitive impairment (Zheng et al., 2017). Here, SMAD2 is linked to amyloidosis.